MARKET

MDGL

MDGL

Madrigal Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

131.44
+2.15
+1.66%
Opening 10:07 04/23 EDT
OPEN
129.36
PREV CLOSE
129.29
HIGH
132.12
LOW
129.36
VOLUME
2.43K
TURNOVER
--
52 WEEK HIGH
137.28
52 WEEK LOW
79.01
MARKET CAP
2.11B
P/E (TTM)
-10.0406
1D
5D
1M
3M
1Y
5Y
Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031
New York, April 15, Apr 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 04/15 14:35
Heterozygous Familial Hypercholesterolemia Drug Market Size, Share, Trends, Growth Rate, Business Opportunity, Demand, Competitive Landscape, Regional Data, and Forecast to 2027
Apr 14, 2021 (The Expresswire) -- Global "Heterozygous Familial Hypercholesterolemia Drug Market" report 2021 covers the present state of Market Share, CAGR,...
The Express Wire · 04/14 06:30
Global Hypopharyngeal Cancer Treatment Market Size, Share, Value, and Competitive Landscape 2024 .
Mar 30, 2021 (Heraldkeepers) -- The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size...
Heraldkeepers · 03/30 13:36
Heterozygous Familial Hypercholesterolemia Drug Market Current Scenario and Trends to (2020-2027) |Ameco Research
pune, India, Tue, 23 Mar 2021 03:35:03 / Comserve Inc. / -- Heterozygous Familial Hypercholesterolemia Drug Market 2020 - Global Industry Research Update,...
Comserve · 03/23 07:36
Billionaire Nicholas Pritzker’s Tao Capital’s Best Stock Ideas and Portfolio
In this article, we discussed Billionaire Nicholas Pritzker’s investment philosophy and his venture capital investments. We also discussed billionaire Nicholas Pritzker’s Tao Capital’s best stock ideas for 2021 to see whether the venture capitalist is in a...
Insider Monkey · 03/18 16:22
Global Hypopharyngeal Cancer Treatment Market Size 2021: Top Countries Segmented By Size, Share, Revenue, Applications and Geography Trends, Industry Trends Under COVID-19, Growth Prospects and Forecasts to 2027
Mar 12, 2021 (The Expresswire) -- “Global Hypopharyngeal Cancer Treatment Market" Research Report2021-2027: Market Analysis and Insights: Global...
The Express Wire · 03/12 06:01
Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Pulmonx (LUNG)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Madrigal Pharmaceuticals (MDGL), Pulmonx (LUNG) and Travere
SmarterAnalyst · 03/03 11:05
Leerink Partners Maintains Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
In a report issued on February 26, Thomas Smith from Leerink Partners maintained a Buy rating on Madrigal Pharmaceuticals (MDGL). The company's shares
SmarterAnalyst · 03/02 14:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MDGL. Analyze the recent business situations of Madrigal Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MDGL stock price target is 171.54 with a high estimate of 225.00 and a low estimate of 126.00.
EPS
Institutional Holdings
Institutions: 204
Institutional Holdings: 12.80M
% Owned: 79.89%
Shares Outstanding: 16.02M
TypeInstitutionsShares
Increased
47
1.43M
New
20
112.85K
Decreased
40
799.83K
Sold Out
13
72.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.10%
Pharmaceuticals & Medical Research
+0.30%
Key Executives
Chairman/Chief Executive Officer/Director
Paul Friedman
Chief Financial Officer/Senior Vice President
Marc Schneebaum
Corporate Executive/Director
Rebecca Taub
Senior Vice President/General Counsel
Brian Lynch
Senior Vice President
Remy Sukhija
Lead Director/Independent Director
Frederick Craves
Independent Director
Kenneth Bate
Independent Director
James Daly
Independent Director
Keith Gollust
Independent Director
Richard Levy
Independent Director
David Milligan
No Data
  • All
  • Financials
  • Insiders
More
About MDGL
Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Webull offers kinds of Madrigal Pharmaceuticals Inc stock information, including NASDAQ:MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.